Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Exacerbation burden in mild asthma: Evidence from the NOVELTY study

Sarowar Muhammad Golam, Mohsen Sadatsafavi, Marianna Alacqua, Richard Beasley, J Mark Fitzgerald, Tim Harrison, Rod Hughes, Hana Müllerová, Jose Maria Olaguibel, Eleni Rapsomaniki, Helen K Reddel, Christer Janson
European Respiratory Journal 2020 56: 969; DOI: 10.1183/13993003.congress-2020.969
Sarowar Muhammad Golam
1AstraZeneca, Cambridge, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Sarowar.Golam@astrazeneca.com
Mohsen Sadatsafavi
2Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marianna Alacqua
1AstraZeneca, Cambridge, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Beasley
3Medical Research Institute of New Zealand, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J Mark Fitzgerald
4Centre for Heart and Lung Health, The Lung Centre Vancouver General Hospital, UBC Institute for Heart and Lung Health, Vancouver, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tim Harrison
5Faculty of Medicine and Health Sciences, Nottingham City Hospital, Nottingham, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rod Hughes
1AstraZeneca, Cambridge, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hana Müllerová
1AstraZeneca, Cambridge, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jose Maria Olaguibel
6Severe Asthma Unit, Complejo Hospitalario de Navarra, Pamplona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eleni Rapsomaniki
1AstraZeneca, Cambridge, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helen K Reddel
7Woolcock Institute of Medical Research, University of Sydney, Sydney, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christer Janson
8Department of Medical Sciences, Uppsala University, Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

Background: Although 50–75% of patients with asthma are reported to have mild asthma, exacerbations may still play a significant role in their disease burden. NOVELTY (NCT02760329) is a global, prospective, observational study of patients with a physician-assigned diagnosis of asthma and/or COPD. Physicians were asked to classify asthma as mild, moderate or severe; no criteria were provided.

Objective: To describe the exacerbation burden of patients with physician-assessed mild asthma in the NOVELTY study.

Methods: Baseline characteristics of patients with physician-assessed mild asthma were described.

Results: Baseline characteristics for 2,175 patients with physician-assessed mild asthma (of 5,940 with asthma) were reported (Table). By physician report, in the past 12 months 527 patients (24%) had ≥1 exacerbation; mean exacerbation rate was 0.4 events/year. Healthcare resource utilisation data were available for 714/867 physician-reported exacerbations; 8% lasted for >1 month and 50% required oral corticosteroids (OCS). By patient report (n=1,494), 835 patients (56%) reported symptom worsening in the past 3 months; 25% of these patients received OCS for symptom worsening (for >2 weeks in 15% of patients who received OCS).

Conclusions: In NOVELTY, many patients with physician-assessed mild asthma had a high exacerbation burden; one in four had ≥1 exacerbation in the past 12 months, and OCS was used in half of exacerbations.

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

  • Exacerbation
  • Asthma
  • Asthma - diagnosis

Footnotes

Cite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 969.

This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.

This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

  • Copyright ©the authors 2020
Previous
Back to top
Vol 56 Issue suppl 64 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Exacerbation burden in mild asthma: Evidence from the NOVELTY study
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Exacerbation burden in mild asthma: Evidence from the NOVELTY study
Sarowar Muhammad Golam, Mohsen Sadatsafavi, Marianna Alacqua, Richard Beasley, J Mark Fitzgerald, Tim Harrison, Rod Hughes, Hana Müllerová, Jose Maria Olaguibel, Eleni Rapsomaniki, Helen K Reddel, Christer Janson
European Respiratory Journal Sep 2020, 56 (suppl 64) 969; DOI: 10.1183/13993003.congress-2020.969

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Exacerbation burden in mild asthma: Evidence from the NOVELTY study
Sarowar Muhammad Golam, Mohsen Sadatsafavi, Marianna Alacqua, Richard Beasley, J Mark Fitzgerald, Tim Harrison, Rod Hughes, Hana Müllerová, Jose Maria Olaguibel, Eleni Rapsomaniki, Helen K Reddel, Christer Janson
European Respiratory Journal Sep 2020, 56 (suppl 64) 969; DOI: 10.1183/13993003.congress-2020.969
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Figures & Data
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • CT evaluations of erector spinae muscle, emphysema, and airway disease for predicting mortality in COPD
  • Alpha-1 antitrypsin deficiency in patients with COPD/emphysema, bronchiectasis and asthma
  • Detecting shortness of breath remotely and accurately using smartphones and vocal biomarkers
Show more Monitoring airway disease

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society